Summary & Overview
HCPCS A9589: Hexaminolevulinate Instillation, 100 mg
HCPCS Level II code A9589 denotes the instillation of hexaminolevulinate hydrochloride, 100 mg, used intravesically to enhance detection of bladder lesions during cystoscopy. This code captures a specialized diagnostic drug administration that supports lesion visualization and biopsy decision-making in urology. Nationally, the code is relevant where enhanced cystoscopic procedures are performed and influences drug handling, billing workflows, and facility charge capture.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and clinical context for A9589, typical sites of service, and which payers commonly reimburse this diagnostic instillation. The publication outlines benchmarks and payer coverage patterns where available, summarizes relevant policy considerations for coding and billing, and provides clinical context on how hexaminolevulinate is used during cystoscopy to improve lesion detection. Data not available in the input is clearly noted where applicable.
Billing Code Overview
HCPCS Level II code A9589 represents instillation of hexaminolevulinate hydrochloride, 100 mg, a diagnostic agent administered intravesically to assist in visualizing bladder lesions during cystoscopy. The service type is a diagnostic intravesical instillation performed as part of a cystoscopic examination. The typical site of service is an outpatient urology setting, ambulatory surgery center, or hospital outpatient department where cystoscopy with enhanced visualization is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing cystoscopic evaluation for suspected non-muscle invasive bladder cancer or surveillance after prior bladder cancer. The patient presents to an outpatient urology clinic or ambulatory surgical center for office cystoscopy or rigid/flexible cystoscopy in the procedure suite. After initial visual inspection of the bladder mucosa, the clinician instills hexaminolevulinate hydrochloride (100 mg, billed as A9589) into the bladder via a catheter and maintains dwell time (typically about 1 hour) to allow selective uptake by dysplastic or neoplastic urothelial cells. Following the incubation period, the bladder is drained and examined with a blue-light (photodynamic) cystoscopy system to identify areas of fluorescence that guide targeted biopsies or transurethral resection of bladder tumor (TURBT). Typical workflow steps: pre-procedure consent and topical/local or monitored anesthesia as indicated, catheter instillation of hexaminolevulinate, timed dwell period during observation, blue-light cystoscopic inspection, documentation of findings, targeted biopsy or resection as clinically indicated, and post-procedure monitoring and discharge instructions. Typical site of service is an outpatient urology clinic, ambulatory surgical center, or hospital outpatient department. Typical patient scenarios include initial evaluation of hematuria, diagnosis of suspected bladder tumor, or surveillance after prior bladder cancer diagnosis.
Coding Specifications
| Modifier | Description | When to Use |
|---|